drugset / Trial / NCT04135898
A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.
Timeline
- Start
- 2019-10-23
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 3 mg/kg | Other |
| Subject | SIBP04 | Monoclonal antibody | 3 mg/kg | Other |
Indications
No indication recorded.